
Tuberculosis prevention
A long-acting injectable for the prevention of latent TB infection

Hepatitis C virus cure
Developing a single-injection cure for hepatitis C virus at the point of diagnosis
Learn more about how we plan to achieve our objectives as we aim to reduce the burden of malaria, tuberculosis and hepatitis C virus in low- and middle-income countries through the LONGEVITY project. In this video you'll find out about our strategy to deploy long-acting injectable medicines to the worlds most in-need communities and reduce the burden that currently stands at 300 million people.
A long-acting injectable for the prevention of latent TB infection
Developing a single-injection cure for hepatitis C virus at the point of diagnosis
Any personal information you provide will be held in accordance with The EU General Data Protection Regulation (GDPR). For more information please see our Privacy notice
The LONGEVITY Project is funded by Unitaid
The project also involves critical partners and collaborators in the Clinton Health Access Initiative, Johns Hopkins University, Medicines Patent Pool, Tandem Nano Ltd., Treatment Action Group and the University of Nebraska Medical Center